We received great news today, when the company released a PR that the Qualification department of the NASDAQ Stock market has granted Evoke Pharma Inc a 180 days extension to comply with the NASDAQ RULING to keep the share price above $1. Evoke has until May 11, 2020 to meet compliance. That will be plenty enough time for Evoke Pharma to resubmit NDA for Gimoti and wait for FDA to approve Evoke Pharma Inc Nasal spray form of Metoclopramide that will be known as Gimoti Nasal spray for the treatment of acute and recurrent of Diabetic Gastroparesis disease. A disease which is found in 80% of women with Diabetic Gastroparesis disease.
When approve Gimoti will be the first non oral advancement treatment to treat acute and recurrents Gastroparesis disease in 40 years.
News 
Market Data 
Discover 
